Wrodzone zespoły miasteniczne
Zapobieganie i profilaktyka

Wrodzone zespoły miasteniczne (CMS) to genetycznie uwarunkowane zaburzenia złącza nerwowo-mięśniowego, wymagające kompleksowego podejścia profilaktycznego. Kluczową rolę odgrywa poradnictwo genetyczne, diagnostyka prenatalna (biopsja kosmówki między 9 a 12 tygodniem ciąży) oraz przedimplantacyjne badania genetyczne, szczególnie w rodzinach z potwierdzonymi mutacjami. Wczesne rozpoznanie, w tym programy badań przesiewowych noworodków, umożliwia wdrożenie leczenia zapobiegającego powikłaniom, takim jak nagła niewydolność oddechowa. Profilaktyka obejmuje także regularne badania kontrolne, nadzór ortopedyczny oraz unikanie czynników zaostrzających objawy, takich jak gorączka, infekcje czy intensywny wysiłek fizyczny.

Wrodzone zespoły miasteniczne – zapobieganie i profilaktyka

Wrodzone zespoły miasteniczne (CMS) to grupa rzadkich chorób genetycznych wpływających na funkcjonowanie złącza nerwowo-mięśniowego. Chociaż nie istnieje obecnie znany sposób całkowitego zapobiegania tym zespołom, dostępne są różne strategie umożliwiające minimalizację ryzyka wystąpienia choroby w rodzinach oraz zapobieganie zaostrzeniom objawów u osób już zdiagnozowanych.123

Poradnictwo genetyczne i diagnostyka prenatalna

Ponieważ CMS jest chorobą dziedziczną, poradnictwo genetyczne stanowi kluczowy element profilaktyki. Jeśli w rodzinie występują przypadki wrodzonych zespołów miastenicznych, zaleca się konsultację genetyczną w celu oceny ryzyka przed planowaniem potomstwa.123 Dla rodzin, w których zidentyfikowano specyficzne mutacje powodujące CMS, dostępne są następujące opcje:

  • Diagnostyka prenatalna oparta na biopsji kosmówki między 9 a 12 tygodniem ciąży
  • Przedimplantacyjne badania genetyczne
  • Badania molekularne określające status genetyczny członków rodziny obarczonych ryzykiem

123

Szczególnie istotne jest wyjaśnienie statusu genetycznego bezobjawowych członków rodziny, zwłaszcza noworodków i małych dzieci, które mogłyby skorzystać z wczesnego leczenia zapobiegającego nagłej niewydolności oddechowej.1

Wczesna diagnostyka i monitorowanie

Wczesne rozpoznanie CMS ma kluczowe znaczenie dla zapobiegania powikłaniom. Zaleca się:

  • Programy badań przesiewowych noworodków pozwalające na wczesną identyfikację niemowląt z CMS
  • Regularne badania medyczne w określonych odstępach czasu wraz z badaniami fizykalnymi
  • Nadzór ortopedyczny nad powikłaniami kręgosłupa i przykurczami

123

Zapobieganie nagłym incydentom oddechowym

Pacjenci z niektórymi typami CMS są szczególnie narażeni na nagłe epizody bezdechu lub niewydolności oddechowej. Dla tych osób zaleca się następujące środki profilaktyczne:12

123

Zapobieganie zaostrzeniom objawów

Osoby z CMS powinny unikać czynników, które mogą nasilać osłabienie mięśni i prowokować niewydolność oddechową:1

  • Unikanie stresorów takich jak gorączka, infekcje lub silne emocje
  • Zapobieganie infekcjom
  • Zapobieganie niedożywieniu wynikającemu z zaburzeń połykania
  • Ograniczenie intensywnego wysiłku fizycznego, który może nasilać objawy kliniczne

123

Zapobieganie niepożądanym reakcjom na leki

Kluczowym elementem profilaktyki jest unikanie leków, które mogą nasilać objawy CMS. Lekarze mogą zalecać alternatywy, jeśli pacjent potrzebuje przyjmować:1

  • Antybiotyki
  • Leki sercowo-naczyniowe
  • Leki stosowane w leczeniu schorzeń psychiatrycznych

1

Szczególnie istotna jest ostrożność przy stosowaniu pirydostygminy u pacjentów z mutacjami w genie DOK7. Nie zaleca się próbowania pirydostygminy przed uzyskaniem wyników badań genetycznych ze względu na jej potencjalne działanie pogarszające objawy u pacjentów z tym typem CMS.1 W przypadku mutacji w genie DOK7, jako leczenie pierwszego wyboru zalecany jest salbutamol.1

Specyficzne zalecenia terapeutyczne w różnych typach CMS

Odpowiednie leczenie jest ważnym elementem profilaktyki powikłań w zależności od typu CMS:12

  • Inhibitory cholinesterazy są skuteczne w większości typów CMS, z wyjątkiem zespołu wolnego kanału (slow channel syndrome) i niedoboru acetylocholinesterazy
  • 3,4-Diaminopirydyna działa presynaptycznie i może być skuteczna w pre- lub postsynaptycznych formach CMS
  • Chinidyna jest pomocna w zespole wolnego kanału

12

Należy pamiętać, że w leczeniu CMS nie zaleca się stosowania steroidów ani tymektomii.1

Przyszłość profilaktyki CMS

Aktualnie prowadzone są intensywne badania mające na celu lepsze zrozumienie wrodzonych zespołów miastenicznych oraz opracowanie nowych strategii leczenia i zapobiegania tym schorzeniom. Wieloaspektowe podejście do badań nad CMS ma na celu poprawę diagnostyki, leczenia i profilaktyki tych chorób.12

Postępy w dziedzinie medycyny molekularnej i genetyki oferują nadzieję na skuteczniejsze strategie profilaktyczne dla rodzin dotkniętych CMS, a lepsza charakterystyka poszczególnych typów CMS pozwala na bardziej precyzyjne zalecenia profilaktyczne odpowiednie dla konkretnych mutacji genetycznych.12

Kolejne rozdziały

Zapraszamy do dalszego czytania naszego leksykonu.

Wybierz kolejny rozdział z menu poniżej, aby otworzyć nową podstronę kompedium wiedzy i uzyskać szczegółowe informację o leku, substancji lub chorobie.

  1. 09.04.2026
  2. www.leksykon.com.pl

Materiały źródłowe

  • #1 Congenital Myasthenic Syndrome (CMS): Symptoms & Treatment
    https://my.clevelandclinic.org/health/diseases/congenital-myasthenic-syndrome
    Theres no known way to prevent congenital myasthenic syndrome. If you plan on expanding your family, you can learn more about your risk of having a child with a genetic condition by talking to a healthcare provider about genetic testing. […] To prevent worsening symptoms, your healthcare provider may recommend alternatives if you need to take the following medications: antibiotics, cardiovascular medications, medications for psychiatric conditions.
  • #1 Congenital myasthenic syndromes | MedLink Neurology
    https://www.medlink.com/articles/congenital-myasthenic-syndromes
    The congenital myasthenic syndromes, like other inherited disorders, can be partially prevented by genetic counseling based on the knowledge of the pattern of inheritance and by prenatal diagnosis based on chorionic villus sampling at 9 to 12 weeks of gestation, provided that the mutations causing the congenital myasthenic syndrome have been identified.
  • #1 Congenital Myasthenic Syndromes | CheckRare
    https://checkrare.com/congenital-myasthenic-syndromes/
    If the pathogenic variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk asymptomatic family members, especially newborns or young children, who could benefit from early treatment to prevent sudden respiratory failure. […] Prophylactic anticholinesterase therapy is used to prevent sudden respiratory insufficiency or apneic attacks provoked by fever or infections in those with pathogenic variants in CHAT or RAPSN. Parents of infants are advised to use apnea monitors and be trained in CPR.
  • #1
    https://continentalhospitals.com/diseases/congenital-myasthenic-syndromes/
    Prevention plays a crucial role in managing congenital myasthenic syndromes (CMS) and improving the quality of life for individuals affected by this rare genetic condition. While there is currently no known cure for CMS, taking preventive measures can help minimize symptoms and complications associated with the condition. One of the key aspects of prevention involves genetic counseling and testing. By identifying individuals who carry the genetic mutations associated with CMS, healthcare professionals can provide appropriate guidance to help them make informed decisions about family planning. This can help reduce the risk of passing on the condition to future generations. […] In addition to genetic counseling, early detection through newborn screening programs can also contribute to prevention efforts. Identifying infants with CMS at an early stage allows for prompt intervention and management strategies, which may help prevent or minimize potential complications. Furthermore, implementing lifestyle modifications and adopting a proactive approach towards managing symptoms are essential preventive measures. This may include regular exercise, maintaining a healthy diet, avoiding triggers that worsen symptoms, and adhering to prescribed medications or treatments.
  • #1 Congenital Myasthenic Syndromes – EyeWiki
    https://eyewiki.org/Congenital_Myasthenic_Syndromes
    If CMS-related mutations are known in a family member, prenatal genetic counseling is recommended, and prenatal tests and preimplantation genetic testing can be conducted.[4] […] Stressors, such as fever, infection, or strong emotions, may exacerbate weakness and even provoke respiratory insufficiency. Patients with mutations most associated with these risks require prophylaxis with anticholinesterase medication.[4]
  • #1 DOK7 congenital myasthenic syndrome: case series and review of literature | BMC Neurology | Full Text
    https://bmcneurol.biomedcentral.com/articles/10.1186/s12883-024-03713-0
    We strongly recommend that neurologists consider CMS in patients with these symptoms and a similar familial history. […] We recommend prescribing salbutamol as the first-choice treatment option for DOK7 patients. […] We do not recommend trying pyridostigmine before genetic results due to its deteriorating effects and the problems that this drug generally causes for DOK7 patients.
  • #1 Congenital myasthenic syndrome | PPT
    https://www.slideshare.net/slideshow/congenital-myasthenic-syndrome-39338481/39338481
    Cholinesterase inhibitors are effective. […] Cholinesterase inhibitors are efficient in all CMSs except slow channel syndrome and acetylcholinesterase deficiency. […] Immediate treatment of respiratory distress. […] Prevention of infections and of malnutrition as a result of swallowing disorders. […] Orthopaedic surveillance of spinal complications and retractions. […] 3,4-Diaminopyridine mode of action is presynaptic, is sometimes effective in pre- or postsynaptic CMSs. […] Quinidine helpful in slow channel.
  • #1
    https://www.omim.org/entry/254210
    A number sign (#) is used with this entry because presynaptic congenital myasthenic syndrome-6 (CMS6) is caused by homozygous or compound heterozygous mutation in the choline acetyltransferase gene (CHAT; 118490) on chromosome 10q11. […] Congenital myasthenic syndromes (CMS) are a group of inherited disorders affecting the neuromuscular junction (NMJ). Patients present clinically with onset of variable muscle weakness between infancy and adulthood. These disorders have been classified according to the location of the defect: presynaptic, synaptic, and postsynaptic. CMS6 is an autosomal recessive CMS resulting from a presynaptic defect; patients have onset of symptoms in infancy or early childhood and tend to have sudden apneic episodes. Treatment with acetylcholinesterase inhibitors may be beneficial (summary by Engel et al., 2015). […] Gieron and Korthals (1985) recommended against use of steroids and thymectomy.
  • #1
    https://grantome.com/grant/NIH/R01-NS109491-03
    Support is requested for a multifaceted investigation of congenital myasthenic syndromes (CMS). […] The CMS will be studied by a multifaceted approach that will improve their diagnosis, treatment, and prevention.
  • #2
    https://continentalhospitals.com/diseases/congenital-myasthenic-syndromes/
    Prevention plays a crucial role in managing congenital myasthenic syndromes (CMS) and improving the quality of life for individuals affected by this rare genetic condition. While there is currently no known cure for CMS, taking preventive measures can help minimize symptoms and complications associated with the condition. One of the key aspects of prevention involves genetic counseling and testing. By identifying individuals who carry the genetic mutations associated with CMS, healthcare professionals can provide appropriate guidance to help them make informed decisions about family planning. This can help reduce the risk of passing on the condition to future generations. […] In addition to genetic counseling, early detection through newborn screening programs can also contribute to prevention efforts. Identifying infants with CMS at an early stage allows for prompt intervention and management strategies, which may help prevent or minimize potential complications. Furthermore, implementing lifestyle modifications and adopting a proactive approach towards managing symptoms are essential preventive measures. This may include regular exercise, maintaining a healthy diet, avoiding triggers that worsen symptoms, and adhering to prescribed medications or treatments.
  • #2 Congenital Myasthenic Syndromes – EyeWiki
    https://eyewiki.org/Congenital_Myasthenic_Syndromes
    If CMS-related mutations are known in a family member, prenatal genetic counseling is recommended, and prenatal tests and preimplantation genetic testing can be conducted.[4] […] Stressors, such as fever, infection, or strong emotions, may exacerbate weakness and even provoke respiratory insufficiency. Patients with mutations most associated with these risks require prophylaxis with anticholinesterase medication.[4]
  • #2 Congenital Myasthenic Syndrome – DoveMed
    https://www.dovemed.com/diseases-conditions/congenital-myasthenic-syndrome
    Congenital Myasthenic Syndrome may not be preventable, since it is a genetic disorder. […] Genetic testing of the expecting parents (and related family members) and prenatal diagnosis (molecular testing of the fetus during pregnancy) may help in understanding the risks better during pregnancy. […] If there is a family history of the condition, then genetic counseling will help assess risks, before planning for a child. […] Active research is currently being performed to explore the possibilities for treatment and prevention of inherited and acquired genetic disorders. […] Regular medical screening at periodic intervals with tests and physical examinations are recommended.
  • #2
    https://www.omim.org/entry/254210
    A number sign (#) is used with this entry because presynaptic congenital myasthenic syndrome-6 (CMS6) is caused by homozygous or compound heterozygous mutation in the choline acetyltransferase gene (CHAT; 118490) on chromosome 10q11. […] Congenital myasthenic syndromes (CMS) are a group of inherited disorders affecting the neuromuscular junction (NMJ). Patients present clinically with onset of variable muscle weakness between infancy and adulthood. These disorders have been classified according to the location of the defect: presynaptic, synaptic, and postsynaptic. CMS6 is an autosomal recessive CMS resulting from a presynaptic defect; patients have onset of symptoms in infancy or early childhood and tend to have sudden apneic episodes. Treatment with acetylcholinesterase inhibitors may be beneficial (summary by Engel et al., 2015). […] Gieron and Korthals (1985) recommended against use of steroids and thymectomy.
  • #2 Congenital myasthenic syndrome | PPT
    https://www.slideshare.net/slideshow/congenital-myasthenic-syndrome-39338481/39338481
    Cholinesterase inhibitors are effective. […] Cholinesterase inhibitors are efficient in all CMSs except slow channel syndrome and acetylcholinesterase deficiency. […] Immediate treatment of respiratory distress. […] Prevention of infections and of malnutrition as a result of swallowing disorders. […] Orthopaedic surveillance of spinal complications and retractions. […] 3,4-Diaminopyridine mode of action is presynaptic, is sometimes effective in pre- or postsynaptic CMSs. […] Quinidine helpful in slow channel.
  • #3 Congenital Myasthenic Syndrome – DoveMed
    https://www.dovemed.com/diseases-conditions/congenital-myasthenic-syndrome
    Congenital Myasthenic Syndrome may not be preventable, since it is a genetic disorder. […] Genetic testing of the expecting parents (and related family members) and prenatal diagnosis (molecular testing of the fetus during pregnancy) may help in understanding the risks better during pregnancy. […] If there is a family history of the condition, then genetic counseling will help assess risks, before planning for a child. […] Active research is currently being performed to explore the possibilities for treatment and prevention of inherited and acquired genetic disorders. […] Regular medical screening at periodic intervals with tests and physical examinations are recommended.
  • #3 Congenital Myasthenic Syndromes | CheckRare
    https://checkrare.com/congenital-myasthenic-syndromes/
    If the pathogenic variants in the family are known, molecular genetic testing can be used to clarify the genetic status of at-risk asymptomatic family members, especially newborns or young children, who could benefit from early treatment to prevent sudden respiratory failure. […] Prophylactic anticholinesterase therapy is used to prevent sudden respiratory insufficiency or apneic attacks provoked by fever or infections in those with pathogenic variants in CHAT or RAPSN. Parents of infants are advised to use apnea monitors and be trained in CPR.
  • #3 Congenital myasthenic syndrome | PPT
    https://www.slideshare.net/slideshow/congenital-myasthenic-syndrome-39338481/39338481
    Cholinesterase inhibitors are effective. […] Cholinesterase inhibitors are efficient in all CMSs except slow channel syndrome and acetylcholinesterase deficiency. […] Immediate treatment of respiratory distress. […] Prevention of infections and of malnutrition as a result of swallowing disorders. […] Orthopaedic surveillance of spinal complications and retractions. […] 3,4-Diaminopyridine mode of action is presynaptic, is sometimes effective in pre- or postsynaptic CMSs. […] Quinidine helpful in slow channel.
  • #3 Congenital Myasthenic Syndrome, CMS in dogs: Canine genetic health condition information — Embarkvet
    https://embarkvet.com/products/dog-health/health-conditions/congenital-myasthenic-syndrome-cms/
    Minimizing intense exercise may help reduce clinical signs. Please follow the recommendations from your veterinarian.